GlaxoSmithKline Plc (GSK)

40.94
0.27 0.66
NYSE : Health Technology
Prev Close 41.21
Open 40.94
Day Low/High 40.94 / 41.00
52 Wk Low/High 31.43 / 48.25
Volume 126.48K
Avg Volume 3.18M
Exchange NYSE
Shares Outstanding 2.51B
Market Cap 102.02B
EPS 2.40
P/E Ratio 23.70
Div & Yield 1.97 (4.86%)
What Are Portfolio Managers Afraid Of?

What Are Portfolio Managers Afraid Of?

They should learn to trust techs, financials.

Obamacare Ruling Means the Debate Is Over

Obamacare Ruling Means the Debate Is Over

As health-care stocks rally, it's time for politicians to move on.

Put Health Care Stocks on Shopping List

Put Health Care Stocks on Shopping List

Have it ready in case market turns volatile.

Health Care Mergers Are Just Getting Started

Deals coming fast and furious in the best group in town.

Portfolio Managers Shop for Growth

Combined Heinz-Kraft heads a long second-quarter list.

Agenus: A Promising Biotech Play

Agenus: A Promising Biotech Play

Approval of malaria vaccine could provide a shot in the arm.

Merger Mania Benefits Mylan

Merger Mania Benefits Mylan

Whether it's acquiring or the acquired, Mylan is building shareholder value.

Profit From the Longer Life Spans, Part 1

Profit From the Longer Life Spans, Part 1

Americans are living much longer these days -- and there are a number of ways to invest.

What to Watch on Wall Street for Wednesday, October 22nd 2014

What to Watch on Wall Street for Wednesday, October 22nd 2014

On Wednesday, October 22nd we continue a busy earnings week, with the country's second largest wireless carrier, AT&T Inc.

A Memo to the Activists

Stop picking on PepsiCo, Allergan and Apple.

What You Need to Know About Female Whistleblowers in the Workplace

What You Need to Know About Female Whistleblowers in the Workplace

Federal Reserve Bank of New York, Goldman Sachs, secretly recorded tapes, and a female employee fired -- those are all real life elements from the headlines circulating around Carmen Segarra.

Five Things to Know Now: Relief Rally

European stocks reach highest level since Jan. 2008.

Five Things to Know Now

European stocks pull back on new worries about Ukraine.

Two Giants Blindsided by Major Trends

Two Giants Blindsided by Major Trends

McDonald's and GlaxoSmithKline are fighting against major turns of the tide.

London Calling

London Calling

Your portfolio could use an English touch.

What to Watch Monday, May 5: Earnings From Drug Giant Pfizer

What to Watch Monday, May 5: Earnings From Drug Giant Pfizer

Investors will be tracking Pfizer's earnings when they report first-quarter results on May 5. Expectations are for earnings of $0.55 a share on sales of $12.07 billion.

GlaxoSmithKline upgraded at Argus

Day Ahead: Awash in Earnings

Day Ahead: Awash in Earnings

Futures point higher; blockbuster drug deal boosts European markets.

The Cloud Is the Prescription

The Cloud Is the Prescription

Medidata Solutions is focusing its cloud-computing offerings on the pharmaceutical industry.

The Turning Point for Defensives?

The Turning Point for Defensives?

The untold story about these stocks is how they have held up.

J&J - More Exciting Than Merck

J&J - More Exciting Than Merck

Johnson & Johnson replaces Merck in AAP given better pipeline and stock upside potential, says AAP Co-Portfolio Manager, Stephanie Link.

Futures Point to Higher Open

Futures Point to Higher Open

U.S. stock futures are pointing to a higher open as Obama presses case for military action in Syria.

GlaxoSmithKline upgraded at JP Morgan

Keep Calm and Carry EWU

Keep Calm and Carry EWU

The UK is the next geographic hotspot. Play it with this ETF.

Glaxo Bribery Claims May be True

Glaxo Bribery Claims May be True

GlaxoSmithKline revealed that some of its senior executives in China may have broken the law.

Benefiting From the Rotation To Cyclicals

Benefiting From the Rotation To Cyclicals

Jim Cramer and Stephanie Link, Co-Portfolio Managers of AAP, discuss how they are trading the current bull market.

New Home Demand Drives Toll

New Home Demand Drives Toll

Luxury homebuilder Toll Brothers reported better-than-expected second quarter earnings on increased demand for new homes.

What's Missing in This Market

What's Missing in This Market

You can't get away from the need for good yield in an era of commodity inflation.

Buffett's Long-Term, High-Dividend Plays

Let's look at five holdings that stayed in his portfolio for at least a year.